Studies have demonstrated that PDL1 was a direct target of the ER BRD4 and the expression inhibition of BRD4 could promote anti‐tumour immunity by modulating PDL1 expression in epithelial ovarian cancer.35 The gene discussed is BRD4; the disease is neoplasm.